Andriy Cherkas1, Rustam Zhuraev. 1. Department of Medicine, Lviv College of Physical Culture, Lviv, Ukraine. cherkasandriy@yahoo.com.
Abstract
BACKGROUND: The studies on heart rate variability (HRV), a key predictor of all-cause mortality, in Marfan syndrome (MS), up to now have not been reported, especially in patients with FBN1 mutations. METHODS: Among 18 MS patients with the phenotype of MS meeting inclusion criteria 15 have had a FBN1 gene mutation. Short electrocardiography records were taken in the supine position and during orthostatic tests. The control group consisted of 30 apparently healthy nonathletes matched by age and gender. RESULTS: Heart rates in MS patients with the FBN1 mutation were increased in both the supine position and orthostatic test (p < 0.001). Most of the time-domain (standard deviation, pNN50) and frequency-domain (total power, very low, low, and high frequency) parameters of HRV were significantly reduced in the MS patients (p < 0.001). CONCLUSIONS: A marked decrease in HRV, documented in the study, may be an important clinical feature in MS patients with confirmed FBN1 gene mutations.
BACKGROUND: The studies on heart rate variability (HRV), a key predictor of all-cause mortality, in Marfan syndrome (MS), up to now have not been reported, especially in patients with FBN1 mutations. METHODS: Among 18 MSpatients with the phenotype of MS meeting inclusion criteria 15 have had a FBN1 gene mutation. Short electrocardiography records were taken in the supine position and during orthostatic tests. The control group consisted of 30 apparently healthy nonathletes matched by age and gender. RESULTS: Heart rates in MSpatients with the FBN1 mutation were increased in both the supine position and orthostatic test (p < 0.001). Most of the time-domain (standard deviation, pNN50) and frequency-domain (total power, very low, low, and high frequency) parameters of HRV were significantly reduced in the MSpatients (p < 0.001). CONCLUSIONS: A marked decrease in HRV, documented in the study, may be an important clinical feature in MSpatients with confirmed FBN1 gene mutations.
Authors: Rustam Zhurayev; Dorien Proost; Dmytro Zerbino; Viktor Fedorenko; Josephina A N Meester; Lut VAN Laer; Bart L Loeys Journal: Genet Res (Camb) Date: 2016-10-11 Impact factor: 1.588
Authors: Felke Steijns; Marjolijn Renard; Marine Vanhomwegen; Petra Vermassen; Jana Desloovere; Robrecht Raedt; Lars E Larsen; Máté I Tóth; Julie De Backer; Patrick Sips Journal: Int J Mol Sci Date: 2020-09-24 Impact factor: 5.923